Collaboration with Major European Lateral Flow Test Developer and Sona Nanotech Inc.

Read the original press release here Halifax, Nova Scotia–(Newsfile Corp. – December 4, 2018) – Sona Nanotech Inc. (CSE: SONA) has signed a collaboration agreement with one of Europe’s largest lateral flow test developers, who will integrate Sona’s nanorod technology into their market-established lateral flow assays. Operon SA, based in Zaragoza, Spain, produces a range of rapid diagnostic test and molecular diagnostic products, which it exports to more than 50 countries. Operon and Sona have agreed to work together to improve the performance of Operon’s currently in-market lateral flow tests to help further establish their market share in the infectious disease arena. If the feasibility study is successful, further development will take place with the expectation to launch products into the market in the first half of 2020. Sona CEO Darren Rowles said: “Sona Nanotech is growing its presence in the lateral flow market, and this agreement with one of the largest and most respected developers in Europe demonstrates the scale of our ambition. We are confident that Sona’s unique gold nanorods will improve the performance of Operon’s tests while remaining cost-competitive, allowing expansion of their market share in this multi-billion-dollar market segment*. I am confident this collaboration is just the start of a long and productive relationship between our companies.” Tomas Toribio, MD of Operon, said: “Operon is always looking for new innovations that will improve the performance of our diagnostic tests and provide a more cost-effective offer for our customers. Sona’s gold nanorods are a unique and impressive technology and we look forward to working together to maximise their potential in our lateral flow assays.” About Sona Nanotech Inc. Sona Nanotech Inc. is a nanotechnology life sciences firm that has developed two proprietary methods for the manufacture of rod-shaped gold nanoparticles. The principal business carried out and intended to be continued by Sona is the development and application of its proprietary technology for use in multiplex diagnostic testing platforms that will improve performance over existing tests in the market. Sona’s gold nanorod particles are CTAB (cetyltrimethylammonium) free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. It is expected that Sona’s gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, pending the approval of various regulatory boards including Health Canada and the FDA. Sona is a publicly listed company on the Canadian Securities Exchange existing under the laws of Nova Scotia, with its operations in Nova Scotia. About Operon Operon has been developing, manufacturing and selling lateral flow tests to the global market for more than 26 years. Its main product lines are:

  • Raw Materials: monoclonal antibodies and recombinant antigens.
  • Immunocromatography: rapid lateral flow tests.
  • Molecular Diagnostic tests: Opegen and OligoGen.
  • Customized services: contract manufacturing of lateral flow tests and raw materials.
For More Information For more information about Sona, please contact: Darren Rowles President and Chief Executive Officer Telephone: (902) 442-7192 Email: Darren Rowles darren@sonanano.com]]>

Business Growth Spurs Expansion to Larger Lab Facilities in Halifax for Sona Nanotech Inc.

About Sona Nanotech Inc. Sona Nanotech Inc. is a nanotechnology life sciences firm that has developed two proprietary methods for the manufacture of rod-shaped gold nanoparticles. The principal business carried out and intended to be continued by Sona is the development and application of its proprietary technology for use in multiplex diagnostic testing platforms that will improve performance over existing tests in the market. Sona’s gold nanorod particles are CTAB (cetyltrimethylammonium) free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. It is expected that Sona’s gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, pending the approval of various regulatory boards including Health Canada and the FDA. Sona is a publicly listed company on the Canadian Securities Exchange existing under the laws of Nova Scotia, with its operations in Nova Scotia. About Innovacorp Innovacorp is Nova Scotia’s early stage venture capital organization. It works to find, fund and foster innovative Nova Scotia start-ups that strive to change the world. Target industries include information technology, life sciences, clean technology and ocean technology. In addition to risk capital, Innovacorp gives entrepreneurs access to world-class incubation facilities, expert advice and other support to help accelerate their companies. For More Information For more information about Sona, please contact: Darren Rowles President and Chief Executive Officer Telephone: (902) 442-7192 Email: Darren Rowles darren@sonanano.com]]>

Sona Nanotech Inc. Announces Listing On Canadian Securities Exchange

Read the original article here. Halifax, Nova Scotia, October 3, 2018 – Sona Nanotech Inc. (CSE: SONA) (“Sona” or the “Company”) is pleased to announce that the Canadian Securities Exchange (CSE) has approved the Company’s application to list its common shares on the CSE.  Effective October 4, 2018, the Company’s shares will commence trading on the CSE under the symbol “SONA”. Overview of Sona Sona is a nano technology life sciences firm that has developed two proprietary methods for the manufacture of rod-shaped gold nanoparticles. The principal business carried out and intended to be continued by Sona is the research and development of its proprietary technology for use in multiplex diagnostic testing platforms that will improve performance over existing tests in the market. Sona’s gold nanorod particles are CTAB (cetyltrimethylammonium) free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. It is expected that Sona’s gold nano technologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, pending the approval of various regulatory boards including Health Canada and the FDA. The Amalgamation Pursuant to the terms of an Amalgamation, every four (4) common shares of Stockport Exploration Inc. were exchanged for one (1) common share of Sona Nanotech Ltd. (the “Sona Shares”); and every 1.5802 common shares of Sona Nanotech Ltd. were exchanged for one (1) Sona Share.  The amalgamation was completed on August 8, 2018. Stockport Exploration Inc. voluntarily delisted its common shares from the TSX Venture Exchange on August 7, 2018, and filed an application for listing its common shares on the CSE. For More Information For more information about Sona, please contact: Darren Rowles President and Chief Executive Officer Telephone: (902) 442-0653 Email: darren@sonanano.com]]>

Colloidal gold, the suspension of gold nanoparticles in liquid, has been used for hundreds of years, from staining glass in the Middle Ages to early experiments with photography in the Victorian era. But it was only 160 years ago that gold nanoparticles were given any serious scientific examination, when scientist Michael Faraday created the first pure sample of colloidal gold in his basement laboratory at the Royal Institute in London. Faraday’s early experiments were forays into what would ultimately become the fields of nanoscience and nanotechnology. Despite many decades of technological development since then, the healthcare potential of gold nanoparticles  is only coming into focus now. This largely reflects recent developments which have allowed scientists to synthesise gold nanoparticles of various shapes and sizes, consistently and at scale. These nanoparticles are also stable, easily functionalised and, critically, biocompatible, meaning they can potentially be used in the body as therapeutic agents.
In combination, these properties mean that gold nanoparticle-based technologies have enormous potential in the healthcare sector. We are already seeing a wide range of possible applications in diagnostic testing, medical treatments and procedures, such as drug delivery, gene therapy, tumour detection and radiotherapy dose enhancement. Innovative applications for gold nanoparticles regularly make headlines in scientific journals and the mainstream press too. Polish scientists, for example, recently patented a formula for artificial saliva that includes gold nanoparticles. The saliva will help patients who have salivary secretion disorder, a condition that means they are unable to swallow, eat and speak. Professor Halina Car from the Medical University of Bialystok said the formula combines at least four properties of natural saliva, while improving lubricity, boosting anti-microbial properties and maintaining hygiene by preventing dental plaque development.
In the US, scientists from the University of Missouri have developed a method of cross-linking gold nanoparticles with collagen gels to treat ageing or damaged skin. Collagen gels are used as soft tissue fillers, to reconstruct soft tissue that has been damaged as a result of age, disease or trauma. The gold nanoparticles, which exhibit high surface reactivity, antioxidant and antimicrobial behaviours, are used to improve the collagen’s resistance to degradation. And in Switzerland, scientists have pioneered a revolutionary approach in the use of gold nanoparticles that could lead to the development of a new generation of broad-spectrum antiviral drugs. Researchers at the Ecole Polytechnique Federale de Lausanne (EPFL) in Switzerland created gold nanoparticles that can attract viruses and destroy them. When injected into the body the nanoparticles mimic human cells and ‘trick’ the viruses into binding with them to infect them. This deforms the viruses and opens them, rendering them harmless. Broad- spectrum antiviral drugs have the potential to cure many deadly viruses that are currently untreatable, from HIV to Ebola. They could also help curb the rise of antimicrobial resistance arising from the over-use of antibiotics. Scientists have pioneered a revolutionary approach in the use of gold nanoparticles that could lead to the development of a new generation of broad-spectrum antiviral drugs.
I have focused my professional attention on gold nanoparticle technology for years, working with lateral flow assays in particular. These are relatively simple devices, used to detect diseases or other conditions outside of a laboratory setting, home pregnancy kits or cost-effective, reliable tests for diseases including malaria and HIV/AIDS. Now, at Sona Nanotech, we have created a unique gold nanoparticle product, synthesising high volumes of high- quality rod-shaped gold nanoparticles without the use  of the toxic chemical cetyltrimethylammonium bromide (CTAB). Ideally suited for diagnostic testing, our gold nanorods are the first in the world to be created without CTAB, which means they can be used inside the body.
They have the potential therefore to be enabling technologies for such medical innovations as non-invasive targeted cell, tumour, tissue and organ treatments including photothermal cancer cell destruction and location-specific drug and pain treatment.
Analysts predict that the global, gold nanoparticles market will grow at a compound annual growth rate of 18.84% between 2017 and 2021, driven largely by increasing demand for medical applications.
Having travelled extensively over the last few months, discussing this breakthrough and identifying new partners and opportunities, I have experienced first-hand the growing demand for innovative gold nanoparticle products. China in particular is a vast untapped market with the healthcare industry being especially focused on lateral flow diagnostic testing products, specifically those targeting heart disease. The country has more than a quarter of the worldwide market for these products but local manufacturers often make gold nanoparticles in-house and quality control is poor. This leads to a sub-optimal final diagnostic product so firms are moving to other methods of clinical diagnostic testing, using markers such as fluorescent markers and quantum dots. While these methods are new and innovative, they are more expensive than gold and don’t necessarily produce better results. Looking ahead, there is an enormous opportunity for lateral flow diagnostic manufacturers in China to create better quality, stable gold nanoparticles, which can be reliably produced at scale. It is not a complex issue and it would help to drive the availability of high-quality, cost-effective healthcare solutions around the world, and Sona is committed to making this happen. For those of us working in the field, it is exciting to see  the technological innovations and breakthroughs involving gold nanoparticles – and the business and investment opportunities that stem from them. Indeed, analysts predict that the global, gold nanoparticles market will grow at a compound annual growth rate of 18.84% between 2017 and 2021, driven largely by increasing demand for medical applications from home or point-of-care testing to drug delivery in cancer treatment. While the quantities of gold used in these types of application are small, the added value and impact to individuals are potentially very significant. This branch of science and technology has much to offer in the twenty-first century and beyond.
]]>

SONA NanoTech creates promising application to treat soft tissue cancers without harmful side-effects

See original article written in Spring 2015 edition of LINK magazine High aspect Gold Nanorods are emerging as a very useful material, with promising applications in “in vivo” medical applications such as; diagnostic imaging and hyperthermal cancer treatment. The use of gold nanorod’s in these applications have been hampered by the fact that current synthesis methods use a chemical called CTAB, which is a toxic substance. The presence of CTAB in the nanoparticles is hindering its use in in vivo applications. SONA Nanotech founders, Dr. Marangoni and Dr. Singh realized that the presence of cytotoxins in gold nanorods was a major impediment to the use of gold nanorods in some of these important in vivo applications and they saw an opportunity to make a difference. Their unique knowledge of surface chemistry and novel surfactant technologies allowed them to develop a method for synthesizing gold nanorod’s without the use of CTAB thereby eliminating the current barriers to adoption for these applications. SONA NanoTech’s method of synthesizing gold nanorod’s could mean the ability to treat soft tissue cancers like skin and prostate cancer very aggressively with no harmful side effects and the ability to pinpoint cancer cells very accurately with enhanced diagnostic imaging. SONA NanoTech’s new synthesis method also has a very high first pass yield compared to conventional methods which will result in a radical reduction in manufacturing costs. This will also facilitate the growth and applications for gold nanorod’s and position SONA to quickly gain a market leadership position. SONA expects to be offering gold nanorod’s by late Spring 2015.]]>